late cornified envelope 2BGenealiases: LEP10 · SPRL1B · XP5
Q-omics provides the consensus-scored LCE2B profile across patient tissues and cancer cell-line models. LCE2B expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, LCE2B is differentially expressed in 1, with the highest sampling consensus in LUSC. Additionally, LCE2B RNA expression shows 8,245 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight BLCA, LUSC, and COAD as cancer lineages where LCE2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LCE2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LCE2B survival associations across molecular data types. LCE2B RNA expression shows survival associations in the most cancer types (15), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LCE2B RNA expression–survival associations across cancer types. High LCE2B expression shows unfavorable associations in BLCA, MESO, UCEC, SKCM, STAD and LUSC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for LCE2B RNA expression.
This table summarizes LCE2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for LCE2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LCE2B shows higher tumor expression in LUSC. The LUSC box plot shows higher LCE2B RNA expression in tumor versus normal tissue (log2 FC = +0.177, t-test p = .001).
This table shows molecular features associated with LCE2B in patient tissues and cancer cell lines. In patient samples, LCE2B shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set. In cancer cell lines, LCE2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LUNG_NSCLC_LUSC.
